The Mechanism of Action of Trastuzumab

Video

Ruth M. O’Regan, MD, director, Translational Breast Cancer Research, professor, hematology and oncology, medical oncology, Winship Cancer Institute, Emory University, discusses the mechanism of action of trastuzumab.

Clinical Pearls

Ruth M. O’Regan, MD, director, Translational Breast Cancer Research, professor, hematology and oncology, medical oncology, Winship Cancer Institute, Emory University, discusses the mechanism of action of trastuzumab.

  • Trastuzumab has an effect on phosphorylation cascades that drive cancers, but that is not believed to be its main mechanism of action. Its effect on the immune system seems to be important.
  • There is a need for a better understanding of trastuzumab’s resistance mechanisms.
Related Videos
Video 5 - "Second-Line Treatment Considerations and Improving Outcomes in Breast Cancer"
Video 4 - "Impressions on Safety Data from EMERALD Subgroup Analysis"
Video 2 - "Importance of Biomarker Testing in Breast Cancer"
Video 3 - "EMERALD: Elacestrant for ER+/HER2- Advanced Breast Cancer"
Video 1 - "Patient Profile: A 49-Year-Old Woman with HR+/HER2- mBC and Liver and Lung Metastases"
Video 7 - "Unmet Needs and Future Directions in HER2+ Breast Cancer"
Related Content
Legislative Changes and Their Impact on Community Oncology Care

Legislative Changes and Their Impact on Community Oncology Care

April 24th 2024
Article

In an interview with Targeted Oncology, Ben Jones identified the key challenges community oncologists are facing due to legislative changes in cancer care policy.

Read More

The Importance of Trastuzumab Deruxtecan in HER2+ Breast Cancer Treatment

The Importance of Trastuzumab Deruxtecan in HER2+ Breast Cancer Treatment

February 28th 2023
Podcast

In season 4, episode 2 of Targeted Talks, Sara A. Hurvitz, MD, discusses key advances in the HER2-positive breast cancer space and interesting ongoing research, namely trastuzumab deruxtecan.

Listen

Batalini Explores Role of UGT1A1 in Patients Treated With Sacituzumab Govitecan for HR+ MBC

Batalini Explores Role of UGT1A1 in Patients Treated With Sacituzumab Govitecan for HR+ MBC

April 22nd 2024
Article

During a Community Case Forum live event in partnership with The Arizona Clinical Oncology Society, Felipe Batalini, MD, discussed the TROPiCS-02 trial of sacituzumab govitecan and the impact of the UGT1A1 status on adverse event frequency.

Read More

Treating HER2-Positive Beast Cancer in the Community Setting

Treating HER2-Positive Beast Cancer in the Community Setting

September 16th 2022
Podcast

In season 3, episode 8 of Targeted Talks, Christie J. Hilton, DO, discusses treating first- and second-line HER2-positive breast cancer.

Listen

Lumisight, Lumicell DVS Gains FDA Approval to Detect Residual Breast Cancer

Lumisight, Lumicell DVS Gains FDA Approval to Detect Residual Breast Cancer

April 18th 2024
Article

The FDA has approved Lumisight and the Lumicell Direct Visualization System for fluorescence imaging in adult patients with breast cancer.

Read More

Dato-DXd Outperforms Docetaxel in Nonsquamous Lung Cancer

Dato-DXd Outperforms Docetaxel in Nonsquamous Lung Cancer

April 15th 2024
Article

Aaron Lisberg, MD, discussed the phase 3 TROPION-Lung01 study which evaluated datopotamab deruxtecan for patients with advanced or metastatic non-small cell lung cancer.

Read More